CalciMedica (CalciMedica) EBIT per Share : $-2.68 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CalciMedica EBIT per Share?

CalciMedica's EBIT per Share for the three months ended in Mar. 2024 was $-0.57. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.68.

During the past 3 years, the average EBIT per Share Growth Rate was 48.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CalciMedica's EBIT per Share or its related term are showing as below:

CALC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -68.3 Med: 11.8 Max: 48.8
Current: 48.8

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of CalciMedica was 48.80% per year. The lowest was -68.30% per year. And the median was 11.80% per year.

CALC's 3-Year EBIT Growth Rate is ranked better than
93.16% of 1302 companies
in the Biotechnology industry
Industry Median: 3.6 vs CALC: 48.80

CalciMedica's EBIT for the three months ended in Mar. 2024 was $-5.77 Mil.

CalciMedica EBIT per Share Historical Data

The historical data trend for CalciMedica's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica EBIT per Share Chart

CalciMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-36.30

-63.07

-22.85

-93.81

-7.63

CalciMedica Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-27.15	-1.16	-0.85	-0.09	-0.57

CalciMedica EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CalciMedica's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-34.247	/	4.486
=	-7.63

CalciMedica's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.767	/	10.047
=	-0.57

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.68

CalciMedica (NAS:CALC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CalciMedica EBIT per Share Related Terms

Thank you for viewing the detailed overview of CalciMedica's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CalciMedica (CalciMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065

Website

https://www.graybug.vision

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

Executives

Robert N Wilson	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny	director, 10 percent owner, officer: Chief Executive Officer	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts	director, 10 percent owner, officer: Chief Business Officer	VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar	officer: Chief Medical Officer	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton	director, 10 percent owner	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p.	10 percent owner	1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn	officer: President and COO	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman	officer: Chief Scientific Officer	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037